| Identification | Back Directory | [Name]
PILSICAINIDE | [CAS]
88069-67-4 | [Synonyms]
SUN-1165
Sunrhythm
PILSICAINIDE
Pilzicainide
Pilsicainida
Pilsicainidum
PILSICAININIDE
Unii-av0X7V6cse
Pilsicainidum [inn-latin]
Pilsicainida [inn-spanish]
PILSICAINIDE(FORRESEARCHONLY)
N-(2，6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7α(5H)-acetamide
N-(2,6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide
N-(2,6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(7H)-acetamide
1H-Pyrrolizine-7A(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-
N-(2,6-Dimethylphenyl)-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetamide
N-(2,6-Dimethylphenyl)-2,3,6,7-tetrahydro-1H-pyrrolizine-7a(5H)-acetamide
N-(2,6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide hydrochloride | [Molecular Formula]
C17H24N2O | [MDL Number]
MFCD00864748 | [MOL File]
88069-67-4.mol | [Molecular Weight]
272.39 |
| Hazard Information | Back Directory | [Chemical Properties]
Pilsicainide: C17H24N2O?HCl?1/2H20. [88069-49-2]. It is obtained from the crystallization of ethanol-diethyl ether. Odorless, bitter taste, melting point 212 ~ 214℃. It is highly soluble in glacial acetic acid and soluble in methanol, ethanol or water. | [Uses]
Pilsicainide is a class IC antiarrhythmic drug, suitable for the treatment of patients with ventricular tachycardia ineffective or intolerable to other antiarrhythmic drugs. | [Definition]
ChEBI: Pilsicainide is a secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan. It has a role as an anti-arrhythmia drug and a sodium channel blocker. It is a secondary carboxamide and an organic heterobicyclic compound. | [Synthesis]
Pilsicainide was obtained from tetrahydrodithickened pyrrole ethyl acetate and 2, 6-dimethylaniline heated and condensed in dioxane at 100℃ under the action of sodium hydride. It is also possible to hydrolyze tetrahydrodithickened pyrrole ethyl acetate and chlorinate it to tetrahydrodithickened pyrrole acetyl chloride, which is then condensed with 2, 6-dimethylaniline. | [in vivo]
Pilsicainide (SUN 1165 free acid; 2 mg/kg; i.v.; once) decreases the conduction velocity in T4-treated rat atrium by decreasing the Max dV/dt and net inward current[1]. | Animal Model: | Male Sprague-Dawley (SD) rats weighing from 200 to 220 g, with levo-thyroxine (T4) treatment[1] | | Dosage: | 2 mg/kg | | Administration: | Bolus injection into right external carotid vein within 2 minutes, once | | Result: | Elongated the QT interval at 15 and 60 minutes after administration.
Shortened P wave and QRS complex durations.
Markedly decreased action potential amplitudes (APA) and Max dV/dt, and significantly lengthened the action potential durations.
|
|
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|